Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias

Part of paid clinical trials in Westwood, Kansas.

Sponsor
John Mascarenhas
Study ID
NCT07447817
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Myelofibrosis
  • Post-essential Thrombocythemia Myelofibrosis
  • Post-polycythemia Vera Myelofibrosis

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Pacritinib — DRUG
    Pacritinib 200mg twice a day (BID) by mouth (PO)
  • Selinexor — DRUG
    Selinexor 60mg once weekly (QW) by mouth (PO)

Study Details

This is a phase II, multicenter, open-label trial evaluating the safety and efficacy of pacritinib and selinexor in JAK inhibitor naïve patients with anemia and thrombocytopenia.

Key Dates

Start date
May 4, 2026
Status verified
Mar 2026
Primary completion
May 24, 2030
Completion
May 24, 2030

Study Design

Enrollment
26 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Pacritinib/Selinexor
    Study participants will receive pacritinib monotherapy (200mg BID orally) for the first cycle (28 days). If they qualify to add on selinexor at any point from Cycle 2 Day 1 to Cycle 4 Day 1, participants will have selinexor (60mg QW orally) added onto their pacritinib regimen.

Primary Outcome Measure

Change in spleen volume [ Time Frame: Baseline and 24 weeks ]

Central Contacts

Locations (3)

FacilityCityStateZIPSite coordinators
The University of Kansas Cancer Center-WestwoodWestwoodKansas66205
Abdulraheem Yacoub (PRINCIPAL_INVESTIGATOR)
Icahn School of Medicine at Mount SinaiNew YorkNew York10029
John Mascarenhas (PRINCIPAL_INVESTIGATOR)
Wake Forest Baptist Health Comprehensive Cancer CenterWinston-SalemNorth Carolina27157
Ruben Mesa (PRINCIPAL_INVESTIGATOR)

Find similar trials in Westwood, KS

By research site
The University of Kansas Cancer Center-Westwood· Westwood, KSIcahn School of Medicine at Mount Sinai· New York, NYWake Forest Baptist Health Comprehensive Cancer Center· Winston-Salem, NC

Related Studies